LeMaitre Vascular Inc. (LMAT) Gains Momentum in Niche Vascular Device Market with Strong International Sales Growth
ByAinvest
Thursday, Sep 11, 2025 11:19 am ET1min read
LMAT--
LeMaitre Vascular, Inc. (LMAT) specializes in vascular disease products, with flagship products including Artegraft biologic graft and Valvulotomes. The company has shown strong growth, particularly in international sales, with revenue projected to grow 13-15% in 2025. LMAT focuses on niche vascular device markets valued under $200 million, with a direct sales force and distributor network in over 90 countries. The accelerated adoption of biologic grafts like Artegraft underscores LMAT's momentum in advancing vascular surgery solutions.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet